Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma

26 Jul 2019

Abstract excerpt

BACKGROUND: Treatment for Cutaneous T Cell Lymphoma (CTCL) is generally not curative. Therefore, selecting therapy that is effective and tolerable is critical to clinical decision-making. Histone deacetylase inhibitors (HDACi), epigenetic modifier drugs, are commonly used but effective in only ~30% of patients. There are no predictive markers of HDACi response and the CTCL histone acetylation landscape remains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous lymphoproliferative disorders research
Share to Histone Deacetylase Inhibitors Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31358475
DOI: 10.1016/j.ebiom.2019.07.053

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphomaPMID 31358475Read ↗

Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell LymphomaSemantic proximity Read ↗

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphomaSemantic proximity Read ↗

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T‐cell lymphomaSemantic proximity Read ↗

Multiomic study of cutaneous T-cell lymphoma reveals single-cell clonal evolution in progression and therapy resistance.Semantic proximity Read ↗

Role of Histone Deacetylases in Drug-Resistant Melanoma: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

Single Cell Resolution Tracking of Cutaneous T-Cell Lymphoma Reveals Clonal Evolution in Disease ProgressionSemantic proximity Read ↗

Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomasSemantic proximity Read ↗

Genetic and epigenetic insights into cutaneous T-cell lymphomaSemantic proximity Read ↗

Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsSemantic proximity Read ↗

Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with ImmunotherapySemantic proximity Read ↗

Novel Biomarkers in Cutaneous T Cell LymphomasSemantic proximity Read ↗

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.